Sunda Energy, Gelion, Coiled Therapeutics, Solvonis Therapeutics, Genflow, Rome Resources

Why It Matters

These milestones signal accelerating growth and commercialisation pathways for small‑cap innovators, offering investors early exposure to high‑upside energy, biotech and mineral assets.

Key Takeaways

• Sunda Energy acquires NZ assets, adding 1,000 barrels/day production
• New acquisition creates third revenue pillar alongside Timor-Leste, Philippines
• Gelion partners with TDK to launch cathode tech in pouch cells
• Coiled Therapeutics doubles clinical benefit rate to 80% with twice‑daily dosing
• Rome Resources reports record‑wide tin intercepts near major DRC mine

Summary

Proactive’s weekly roundup highlighted a series of catalyst‑driven updates from eight small‑cap companies spanning energy, biotech and mining.

Sunda Energy secured a transformational acquisition in New Zealand, adding over 1,000 barrels of oil per day and creating a third revenue pillar alongside its Timor‑Leste and Philippines assets. Gelion announced an expanded partnership with TDK, moving its high‑energy cathode into a pouch‑cell format aimed at the fast‑growing drone battery market. Coiled Therapeutics reported its oncology candidate AO‑252 doubled its clinical benefit rate to 80% after moving to twice‑daily dosing, prompting plans for combination trials.

Solvonis Therapeutics obtained two U.S. patents covering distinct chemical series for a PTSD treatment, addressing an unmet market of roughly 20 million patients. Genflow Biosciences observed three‑month durability of effect in a canine gene‑therapy trial, suggesting a potential one‑time treatment model. Rome Resources delivered its strongest tin intercepts at the Kalayi prospect in the DRC, with wider zones located just eight kilometres from a mine that supplies over 7 % of global tin.

Collectively, these developments enhance cash‑flow visibility, broaden market addressable opportunities and de‑risk exploration pipelines, positioning the featured companies for heightened investor attention and possible valuation upgrades.

Original Description

Sunda Energy PLC (AIM:SNDA) has made a transformational acquisition in New Zealand, giving it immediate production of over 1,000 barrels a day. The deal adds a third pillar to its portfolio alongside assets in Timor-Leste and the Philippines.

Gelion PLC (AIM:GELN, OTC:GELNF, FRA:X0S) has expanded its partnership with TDK Corporation, successfully moving its battery cathode technology into a pouch cell format. TDK dominates the drone battery market, and prototype results are expected soon.

Coiled Therapeutics (AIM:COIL) has reported a jump in clinical benefit rate from 40% to 80% for its cancer drug AO-252 after switching to twice-daily dosing. The company now plans combination trials with multiple data readouts expected this year.

Solvonis Therapeutics PLC (LSE:SVNS) has secured two US patents for its PTSD treatment programme, covering two distinct chemical series. There are around 20 million PTSD sufferers across key markets, and currently no approved treatments exist.

Genflow Biosciences (LSE:GENF, OTCQB:GENFF, FRA:WQ5) says benefits from its gene therapy trial in dogs have persisted three months after treatment stopped. That durability raises the possibility of a one-time intervention rather than ongoing treatment.

Rome Resources PLC (AIM:RMR, FRA:33R) has delivered its strongest ever drilling results at its Kalayi tin prospect in the Democratic Republic of Congo, with significantly wider intercepts than previous campaigns. The deposit sits just eight kilometres from a mine producing over 7% of the world's tin.

Follow us and subscribe on YouTube, our social channels, and on proactiveinvestors.co.uk.